Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration

The British Journal of Ophthalmology
Irmela MantelFrancine Behar-Cohen

Abstract

Vascular endothelial growth factor (VEGF) is a key player in the pathogenesis of neovascular age-related macular degeneration (nAMD) and is also involved in the final common pathway of antidepressant medication. This study investigated the relationship between the need for anti-VEGF retreatment in patients with nAMD and antidepressant medication, and the potential impact of ocular structural factors. Data from two identical prospective 2-year treatment protocols using ranibizumab or aflibercept in a variable-dosing regimen ('Observe-and-Plan') were analysed. Retreatment requirement was compared with antidepressant medication intake (primary outcome) and a variety of ocular factors from baseline and from month 3 response (secondary outcomes), using univariate and multivariate analyses. Of the 206 included patients (227 eyes), 19 were on antidepressant medication. Their nAMD eyes significantly more often had pigment epithelium detachment (PED, p=0.04). Multivariate analysis revealed a significant association between anti-VEGF retreatment requirement and antidepressant medication use (p=0.027), as well as thicker central retinal thickness at month 3 (p<0.0001) and month 3 PED height (p=0.001). This study provides evidence that tre...Continue Reading

References

Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Jan 30, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jun-Ichi IgaTetsuro Ohmori
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jennifer L Warner-Schmidt, Ronald S Duman
Jun 26, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joshua GreeneRonald S Duman
Jul 3, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jeong-Sik LeeHyeon Son
Apr 30, 2011·The New England Journal of Medicine·UNKNOWN CATT Research GroupGlenn J Jaffe
Aug 25, 2011·Journal of Affective Disorders·Bun-Hee Lee, Yong-Ku Kim
Oct 23, 2012·Ophthalmology·Jeffrey S HeierUNKNOWN VIEW 1 and VIEW 2 Study Groups
Jul 23, 2013·Journal of Affective Disorders·Michele FornaroMatteo Martino
Apr 1, 2015·Ophthalmology·Thomas A CiullaUNKNOWN Comparison of Age-Related Macular Degeneration Treatments Trials Research Group
Jul 29, 2016·Retina·Anastasia TrabandBrian L VanderBeek
Mar 8, 2017·Translational Psychiatry·T XieS Visvikis-Siest
Aug 12, 2017·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Parmis ParvinIrmela Mantel

❮ Previous
Next ❯

Software Mentioned

Excel
JMP

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.